TORONTO, Canada (AP/WJZ)– Clinical trials for an Ebola vaccine will be tested on humans in a Maryland laboratory Monday.
The experimental Canadian-made vaccine showed promise in tests on primates.READ MORE: More Than 1,000 Students In Quarantine In Anne Arundel County; County Executive Supports Vaccine Mandate For All Students
READ MORE ON EBOLA VACCINES: Baltimore Doctor In Mali Administering First Trials Of Ebola Vaccine |UMd. Plays Role In Ebola Vaccine Test In Africa
The vaccine will be tested on healthy individuals Monday to see how well it works, whether there are side effects and what the proper dosage is, Canadian Health Minister Rona Ambrose said.READ MORE: Residents & Business Owners Question The Future Of The Inner Harbor's Gallery Mall
Studies in primates have shown this vaccine works both to prevent infection when given before exposure and to increase survival chances when given quickly after exposure.
A small Iowa-based company called NewLink Genetics holds the license for the vaccine and the trials are set to begin in a lab in Maryland. Ambrose said the results are expected in December.
NewLink said earlier this month that at least five clinical trials involving the vaccine, known as VSV-EBOV, would soon be underway in the United States, Germany, Switzerland and in an unnamed African country that is not battling Ebola.MORE NEWS: Shortage In COVID Testing Kits Driving Up Lab-Based Demand
(Copyright 2013 by The Associated Press. All Rights Reserved.)